VivoSeq
Gastroenterology

Diverticulitis

20

Pipeline Programs↗

3

Active Trials↗

11

Companies Involved↗

Diverticulitis is an emerging landscape with 20 programs across 11 companies. The most active players are Merck & Co., Salix, Iterum Therapeutics, International Limited. 5 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

75/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 2S

Salix

1 program

Phase 2I

Iterum Therapeutics, International Limited

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2Takeda logo

Takeda

3 programs

Phase 3Ferring logo

Ferring

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

19

clinical trials

Completed9 · 47%
Unknown status4 · 21%
Terminated3 · 16%
Active, not recruiting1 · 5%
Recruiting1 · 5%
Enrolling by invitation1 · 5%

Clinical Trials

Trial Activity

19 trials

Clinical Trial With MBK-01, Intestinal Microbiota Capsules, for the Treatment of Patients With Recurrent Diverticulitis
Recruiting·MMikrobiomik Healthcare Company S.L.·Phase 2·NCT06687382·81 enrolled
FMT in Uncomplicated Diverticulitis
Active, not recruiting·—·Phase 1·NCT05373784·10 enrolled
Effectiveness and Safety of Outpatient Treatment of Uncomplicated Acute Diverticulitis Without Antibiotics
Enrolling by invitation·—·N/A·NCT06517264·282 enrolled
Symptomatic Treatment of Acute Uncomplicated Diverticulitis
Completed·HHelsinki University Central Hospital·N/A·NCT02219698·158 enrolled
Antibiotic Therapy of Acute Uncomplicated Colonic Diverticulitis
Completed·UUppsala University·N/A·NCT01008488·600 enrolled
Asacol Acute Diverticulitis(DIVA)Study
Completed·—·Phase 2·NCT00554099·117 enrolled
Randomized Clinical Trial to Compare the Treatment of Mild Acute Diverticulitis With or Without Antibiotics
Completed·CCorporacion Parc Tauli·Phase 4·NCT02785549·480 enrolled
Trial Assessing the Efficacy of a Short Course of Intravenous Antibiotic Followed by Oral Antibiotic in Uncomplicated Acute Diverticulitis
Completed·CConsorci Sanitari de Terrassa·Phase 4·NCT00917592·50 enrolled
Prevention of Recurrence of Diverticulitis
Completed·Takeda logoTakeda·Phase 3·NCT00545103·592 enrolled
Evaluation of Efficacy of Mesalamine in the Long-term Prevention of Diverticulitis Flares
Completed·SSOFAR S.p.A.·Phase 3·NCT01120340·105 enrolled
Prevention of Recurrence of Diverticulitis
Completed·Takeda logoTakeda·Phase 3·NCT00545740·590 enrolled
Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis
Completed·—·Phase 2·NCT01847664·204 enrolled
Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.
Terminated·—·Phase 2/3·NCT03469050·193 enrolled
Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis
Terminated·—·Phase 3·NCT00695643·345 enrolled
Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis
Terminated·—·Phase 3·NCT01038739·330 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)